{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:03:10Z","timestamp":1792134190141,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000014","name":"Canadian Blood Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcyt.2026.102898","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:06:56Z","timestamp":1776985616000},"page":"102898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A scoping review of gene editing in clinical trials: identifying aspects of trial design to accelerate clinical adoption"],"prefix":"10.1016","volume":"28","author":[{"given":"Gabrielle","family":"Khare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1446-0112","authenticated-orcid":false,"given":"Justine","family":"Hanotaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram Vasudevan","family":"Nampoothiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinad","family":"Maganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-8289","authenticated-orcid":false,"given":"David S.","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7794","key":"10.1016\/j.jcyt.2026.102898_bib0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"issue":"6629","key":"10.1016\/j.jcyt.2026.102898_bib0002","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102898_bib0003","unstructured":"FDA. FDA approves first gene therapies to treat patients with sickle cell disease"},{"key":"10.1016\/j.jcyt.2026.102898_bib0004","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jcyt.2026.102898_bib0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcyt.2021.10.010","article-title":"Use of CRISPR\/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: a systematic review and meta-analysis of preclinical studies","volume":"24","author":"Maganti","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102898_bib0006","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/sctm.20-0520","article-title":"Persistence of CRISPR\/Cas9 gene edited hematopoietic stem cells following transplantation: a systematic review and meta-analysis of preclinical studies","volume":"10","author":"Maganti","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.jcyt.2026.102898_bib0009","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 Guideline Statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcyt.2026.102898_bib0011","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2026.102898_bib0012","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0013","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR-Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102898_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcyt.2026.102898_bib0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","article-title":"Safety and activity of CTX130, a CD70-targeted allogenic CRISPR-Cas9-engineered CAR-T cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open label, phase I, dose escalation study","volume":"26","author":"Iyer","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102898_bib0016","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","article-title":"CD7 targeted \"off the shelf\" CAR-T demonstrates robust in vivo expansion and high efficiency in the treatment of patients with relapsed\/refractory T-cell malignancies","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102898_bib0017","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase I clinical trial of CRISPR engineered CAR19 universal T-cells for treatment of children with refractory B-cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0018","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102898_bib0019","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0020","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0021","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","article-title":"CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b20\/\u03b20 transfusion-dependant \u03b2-thalassemia","volume":"28","author":"Fu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-74716-7","article-title":"Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease","volume":"14","author":"Lessard","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102898_bib0023","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0024","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102898_bib0026","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jcyt.2026.102898_bib0027","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0028","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","article-title":"Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial","volume":"26","author":"Lou","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102898_bib0029","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102898_bib0030","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jcyt.2026.102898_bib0031","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with Nexiguran Ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0033","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102898_bib0034","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0035","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for CEP290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0036","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2023.08.021","article-title":"In vivo CRISPR gene editing in patients with herpetic stromal keratitis","volume":"31","author":"Wei","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102898_bib0037","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4-T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102898_bib0038","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2026.102898_bib0039","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2026.102898_bib0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/genes14010129","article-title":"Recent advances in genome-engineering strategies","volume":"14","author":"Boti","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jcyt.2026.102898_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jcyt.2026.102898_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2025.108750","article-title":"Methods for detecting off-target effects of CRISPR\/Cas9","volume":"86","author":"Xu","year":"2026","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.jcyt.2026.102898_bib0043","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102898_bib0044","first-page":"21","article-title":"Recent advancements in reducing the off-target effect of CRISPR-Cas9 genome editing","volume":"18","author":"Mengstie","year":"2024","journal-title":"Biologics"},{"key":"10.1016\/j.jcyt.2026.102898_bib0045","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41434-021-00232-2","article-title":"Cas9-directed immune tolerance in humans-a model to evaluate regulatory T cells in gene therapy?","volume":"28","author":"Wagner","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.jcyt.2026.102898_bib0046","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40472-019-00237-2","article-title":"Evasion of pre-existing immunity to Cas9: a prerequisite for successful genome editing in vivo?","volume":"6","author":"Wignakumar","year":"2019","journal-title":"Curr Transpl Rep"},{"key":"10.1016\/j.jcyt.2026.102898_bib0047","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40259-023-00610-9","article-title":"Base editing and prime editing: potential therapeutic options for rare and common diseases","volume":"37","author":"Testa","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.jcyt.2026.102898_bib0048","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtm.2021.04.001","article-title":"Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs","volume":"21","author":"Drago","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2026.102898_bib0049","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1503\/cmaj.181657","article-title":"CRISPR babies\": what does this mean for science and Canada?","volume":"191","author":"Knoppers","year":"2019","journal-title":"CMAJ"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926008595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:23:17Z","timestamp":1788362597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926008595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1465324926008595"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102898","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A scoping review of gene editing in clinical trials: identifying aspects of trial design to accelerate clinical adoption","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102898"}}